Fore Biotherapeutics appoints Matthew E. Ros as CEO

Clinical stage biotechnology company Fore Biotherapeutics has appointed Matthew E. Ros as Chief Executive Officer and Director of the Board.

Prior to joining Fore, Ros was Executive Vice President and Chief Strategy and Business Officer of Epizyme, Inc., a commercial-stage and publicly traded biopharmaceutical company developing novel epigenetic therapies.

Ros has held leadership positions across sales, marketing, franchise strategy and business operations, having began his career in the Oncology division at Bristol Myers Squibb.

Dieter Weinand, the Chairman of the Board of Directors commented:

“After an extensive search, we are delighted and very excited to welcome Matt as our next CEO. Matt brings enormous experience to grow and scale Fore as an innovative biotech given his track record of success in both mature and emerging life sciences companies.

“He is the right leader for our company, and the Board and I are delighted to partner with Matt to navigate Fore’s path to continued success.”

Ros said:

“I am honoured and humbled to lead Fore and work alongside the incredibly talented management team to build upon what has been accomplished to date.

“Fore is poised to develop targeted treatments that fundamentally transform the way cancer is treated. The company’s functional genomics platform provides us with the opportunity to serve cancer patients with novel, innovative medicines.”

Fore focuses on hyper-targeting precision oncology therapies for patients with unaddressed tumour mutations.

The Company expects to complete enrolment to its Phase 1/2a study in the coming months, and to launch a registrational Phase 2 study of its clinical Class I/II BRAF inhibitor, FORE8394.

FORE8394 has demonstrated clinical safety and early efficacy signals in an ongoing Phase 1/2a clinical trial.